Advice for Travelers | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

118

June 1, 2012

View Complete Issue Table of Contents 2019

Advice for Travelers

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Advice for Travelers

June 1, 2012 (Issue: 118)

Superseded by The Medical Letter "Advice for Travelers" - Issue 1582, October 7, 2019

Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC)...more

Show References Hide References

1. DR Hill et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.

2. Adult immunization. Treat Guidel Med Lett 2011; 9:75.

3. General recommendations on immunizations – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(2):1.

4. RM Klevens et al. The evolving epidemiology of hepatitis A in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med 2010; 170:1811.

5. S Iwarson et al. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004; 11:120.

6. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56:1080.

7. R Steffen. Influenza in travelers: epidemiology, risk, prevention, and control issues. Curr Infect Dis Rep 2010; 12:181.

8. Influenza vaccine for 2011-2012. Med Lett Drugs Ther 2011; 53:81.

9. Centers for Disease Control and Prevention (CDC). Use of northern hemisphere influenza vaccines by travelers to the southern hemisphere. MMWR Morb Mortal Weekly Rep 2009; 58:312.

10. SL Hills et al. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010; 82:930.

11. E Mirzaian et al. Mosquito-borne illness in travelers: a review of risk and prevention. Pharmacotherapy 2010; 30:1031.

12. A new Japanese encephalitis vaccine (Ixiaro). Med Lett Drugs Ther 2009; 51:66.

13. SB Halstead and SJ Thomas. Japanese encephalitis: new options for active immunization. Clin Infect Dis 2010; 50:1155.

14. CDC. Update on Japanese encephalitis vaccine for children: United States, May 2011. MMWR Morb Mortal Wkly Rep 2011; 60:644.

15. A Kaltenböck et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834.

16. PJ Edelson and JA Anderson. Reported cases of measles in international air travelers to the United States, August 2005-March 2008. J Travel Med 2011; 18:178.

17. CDC. Measles imported by returning US travelers aged 6-23 months, 2001-2011. MMWR Morb Mortal Wkly Rep 2011; 60:397.

18. R Steffen. The risk of meningococcal disease in travels and current recommendations for prevention. J Travel Med 2010; 17 Suppl: 9.

19. A new conjugate meningococcal vaccine (Menveo). Med Lett Drugs Ther 2010; 52:59.

20. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.

21. Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses—worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep 2011; 60:846.

22. C Malerczyk et al. Imported human rabies cases in Europe, the United States, and Japan, 1990-2010. J Travel Med 2011; 18:402.

23. CE Rupprecht and RV Gibbons. Clinical practice. Prophylaxis against rabies. N Engl J Med 2004; 351:2626.

24. CE Rupprecht et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2010; 59(RR-2):1.

25. Adacel and Boostrix: Tdap vaccines for adolescents and adults. Med Lett Drugs Ther 2006; 48:5.

26. ACIP Provisional Tdap Recommendations. March 21, 2012. Available at www.cdc.gov/vaccines/recs/provisional/Tdap-feb2012.htm. Accessed May 16, 2012.

27. MF Lynch et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859.

28. JA Whitaker et al. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009; 16:46.

29. JE Staples et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-7):1.

30. N Bhadelia et al. The HIV-positive traveler. Am J Med 2007; 120:574.

31. AW McMahon et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007; 25:1727.

32. RE Thomas et al. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 2012; 86:359.

33. MF Farez and J Correale. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011; 68:1267.

34. S Kuhn et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 2011; 183:E243.

35. RC Charles and ET Ryan. Cholera in the 21st century. Curr Opin Infect Dis 2011; 24:472.

36. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:117.

37. A Banzhoff et al. Protection against tick-borne encephalitis (TBE) for people living in and traveling to TBE-endemic areas. Travel Med Infect Dis 2008; 6:331.

38. U Kunze. Is there a need for a travel vaccination against tick-borne encephalitis? Travel Med Infect Dis 2008; 6:380.

39. N Apelt et al. The prevalence of Norovirus in returning international travelers with diarrhea. BMC Infect Dis 2010; 10:131.

40. HL DuPont et al. Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med 2009; 16:161.

41. D Jain et al. Campylobacter species and drug resistance in a north Indian rural community. Trans R Soc Trop Med Hyg 2005; 99:207.

42. DR Tribble et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338.

43. KS Hong and JS Kim. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol 2011; 4:227.

44. HL DuPont et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med 2009; 16:149.

45. HL DuPont et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805.

46. AW Armstrong et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. J Travel Med 2010; 17:392.

47. F Martinez-Sandoval et al. Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med 2010; 17:111.

48. DO Freedman. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.

49. PJ van Genderen et al. The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of Plasmodium falciparum malaria in non-immune travelers and expatriates [corrected]. J Travel Med 2007; 14:92.

50. E Schwartz et al. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 2003; 37:450.

51. A Färnert et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 2003; 326:628.

52. S Kuhn et al. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a nonimmune North American traveller to west Africa. Am J Trop Med Hyg 2005; 72:407.

53. CT Happi et al. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malaria J 2006; 5:82.

54. J Ling et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825.

55. J Soto et al. Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers. Am J Trop Med Hyg 2006; 75:430.

56. LH Chen et al. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.

57. P Schlagenhauf et al. Use of mefloquine in children – a review of dosage, pharmacokinetics and tolerability data. Malar J 2011; 10:292.

58. DR Hill et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.

59. P Schlagenhauf et al. Pregnancy and fetal outcomes after exposure to Mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54:e124. Epub 2012 Apr 10.

60. MH Irvine et al. Prophylactic use of antimalarials during pregnancy. Can Fam Physician 2011; 57:1279.

61. R McGready et al. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg 2001; 65:285.

62. Sunscreens: an update. Med Lett Drugs Ther 2008; 50:70.

63. A Badolo et al. Evaluation of the sensitivity of Aedes aegypti and Anopheles gambiae complex mosquitoes to two insect repellents: DEET and KBR 3023. Trop Med Int Health 2004; 9:330.

64. SP Frances et al. Laboratory and field evaluation of commercial repellent formulations against mosquitoes (diptera: culcidae) in Queensland, Australia. Aust J Entomol 2005; 44:431.

65. C Constantini et al. Field evaluation of the efficacy and persistence of insect repellents DEET, IR3535, and KBR 3023 against Anopheles gambiae complex and other Afrotropical vector mosquitoes. Trans R Soc Trop Med Hyg 2004; 98:644.

66. CP Simmons et al. Dengue. N Engl J Med 2012; 366:1423.

67. MG Guzman et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8(12 Suppl):S7.

68. A Pavli and HC Maltezou. Travel-acquired leptospirosis. J Travel Med 2008; 15:447.

69. SA Gallagher and PH Hackett. High-altitude illness. Emerg Med Clin North Am 2004; 22:329.

70. MJ McInnis et al. Evidence for a genetic basis for altitude illness: 2010 update. High Alt Med Biol 2010; 11:349.

71. AM Luks et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21:146.

72. BL Strom et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.

73. D Chandra et al. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 2009; 151:180.

74. SR Kahn et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.

75. M Clarke et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database Syst Rev 2006; (2):CD004002.

76. MR Cesarone et al. Venous thrombosis from air travel: the LONFLIT3 study–prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology 2002; 53:1.

77. RL Sack. Clinical practice. Jet lag. N Engl J Med 2010; 362:440.

78. J Waterhouse et al. Jet lag: trends and coping strategies. Lancet 2007; 369:1117.

79. AO Jamieson et al. Zolpidem reduces the sleep disturbance of jet lag. Sleep Med 2001; 2:423.

80. RP Rosenberg et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc 2010; 85:630.

81. JF Golding and MA Gresty. Motion sickness. Curr Opin Neurol 2005; 18:29.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.